DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20160464

Comparative study of theophylline and doxofylline in the treatment of stable chronic obstructive pulmonary disease

Panduranga Rao Nagawaram, Vashishta Kanchanpally

Abstract


Background: COPD is one of the major public health problems worldwide. Theophylline has been used in the treatment of COPD for decades. Doxofylline a new theophylline congener has been claimed to have better safety profile. The study was undertaken to compare theophylline and doxophylline at doses recommended and commonly used in clinical practice.

Methods: The study was conducted in patients of COPD in TB chest department of Osmania medical college hospital. It was an open label, randomized, prospective parallel group study of 12 weeks duration. A total of 40 patients were divided in two groups. Group I was administered 400 mg theophylline sustained release tablets once daily orally and group II was administered doxofylline 400 mg twice a day orally. Spirometric variables symptom score, and adverse effects were recorded on days 0, week 1, week 6 and 12 of therapy. Data were compared and statistical analysis was performed using the Prism Graphpad 6, USA.

Results: There was no statistically significant difference with respect to spirometric variables and symptom score in the two groups and no significant difference in two groups with respect to side effects (p>0.05).

Conclusions: Both doxofylline and theophylline significantly improved spirometric values and there was significant improvement in symptoms – cough, shortness of breath and nocturnal severity of symptoms. There was a significant reduction in the use of at rescue medication during the treatment with both the drugs.


Keywords


COPD, Doxofylline, Theophylline, Spirometry

Full Text:

PDF

References


Gupta D, Agarwal R, Aggarwal AN. Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India. 2013;30(3):228-67.

World Health Organisation-Burden of COPD. [Internet]. 2015. Available from: – http://www.who.int/respiratory/copd/burden/en/

Salvi S, Agarwal A. India needs a national COPD prevention and Control program. J Asso Physicians India. 2012;60:5-7.

Essayan DM. Cyclic nucleotide phosphodiesterases. J Allergy Clin Immunol. 2001;108(5):671-80.

Deree J, Martins JO, Melbostad H, Loomis WH, Coimbra R. Insights into the Regulation of TNF-α Production in Human Mononuclear Cells: The Effects of Non-Specific Phosphodiesterase Inhibition. Clinics (Sao Paulo). 2008;63(3):321-8.

Marques LJ, Zheng L, Poulakis N, Guzman J, Costabel U. Pentoxifylline inhibits TNF-alpha production from human alveolar macrophages. Am J Respir Crit Care Med. 1999;159(2):508-11.

Peters-Golden M, Canetti C, Mancuso P, Coffey MJ. Leukotrienes: underappreciated mediators of innate immune responses. J Immunol. 2005;174(2):589-94.

Daly JW, Jacobson KA, Ukena D. Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230(1):41-63.

Santra CK. Treatment of moderate chronic obstructive pulmonary disease (stable) with doxofylline compared with slow release theophylline--a multicentre trial. J Indian Med Assoc. 2008;106(12):791-4.

Melillo G, Balzano G, Jodice F, De Felice A, Campisi V, Capone M. Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial. Int J Clin Pharmacol Res. 1989;9:397-405.

Goldstein MF, Chervinsky P. Efficacy and safety of doxofylline compared to theophylline in chronic reversible asthma – a double-blind randomised placebo-controlled multicentre clinical trial. Med Sci Monit. 2002;8:297-304.